143 related articles for article (PubMed ID: 2570847)
1. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals.
Ogawa Y; Okada H; Heya T; Shimamoto T
J Pharm Pharmacol; 1989 Jul; 41(7):439-44. PubMed ID: 2570847
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
[TBL] [Abstract][Full Text] [Related]
3. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
Okada H; Heya T; Ogawa Y; Shimamoto T
J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
[TBL] [Abstract][Full Text] [Related]
4. Endocrinological studies on TAP-144-SR, a sustained-release formulation of a potent GnRH agonist (D-Leu6-[des-Gly10-NH2]-GnRH ethylamide), in male rats.
Sudo K; Masaki T; Shiota K; Kawase M; Fujita T
Endocrinol Jpn; 1990 Oct; 37(5):685-93. PubMed ID: 2128273
[TBL] [Abstract][Full Text] [Related]
5. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
6. Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate.
Okada H; Heya T; Ogawa Y; Toguchi H; Shimamoto T
Pharm Res; 1991 May; 8(5):584-7. PubMed ID: 1907735
[TBL] [Abstract][Full Text] [Related]
7. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion.
Zheng JY; Fulu MY
Int J Pharm; 2006 Jan; 307(2):209-15. PubMed ID: 16300912
[TBL] [Abstract][Full Text] [Related]
8. Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats.
Pinski J; Yano T; Groot K; Milovanovic S; Schally AV
Peptides; 1992; 13(5):905-11. PubMed ID: 1336188
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate.
Okada H; Inoue Y; Heya T; Ueno H; Ogawa Y; Toguchi H
Pharm Res; 1991 Jun; 8(6):787-91. PubMed ID: 1905810
[TBL] [Abstract][Full Text] [Related]
10. Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs.
Okada H; Doken Y; Ogawa Y; Toguchi H
Pharm Res; 1994 Aug; 11(8):1199-203. PubMed ID: 7971724
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance.
Toguchi H
J Int Med Res; 1990; 18 Suppl 1():35-41. PubMed ID: 2138986
[TBL] [Abstract][Full Text] [Related]
12. Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.
Cukierski MJ; Johnson PA; Beck JC
Int J Toxicol; 2001; 20(6):369-81. PubMed ID: 11797819
[TBL] [Abstract][Full Text] [Related]
13. Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats.
Kostanski JW; Dani BA; Schrier B; DeLuca PP
Pharm Res; 2000 Apr; 17(4):445-50. PubMed ID: 10870989
[TBL] [Abstract][Full Text] [Related]
14. Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients.
Mazzei T; Mini E; Rizzo M; Periti P
J Int Med Res; 1990; 18 Suppl 1():42-56. PubMed ID: 2108885
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists.
Redding TW; Schally AV
J Endocrinol; 1990 Aug; 126(2):309-15. PubMed ID: 2144873
[TBL] [Abstract][Full Text] [Related]
16. Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75).
Pinski J; Yano T; Szepeshazi K; Groot K; Schally AV
J Androl; 1993; 14(3):164-9. PubMed ID: 8407570
[TBL] [Abstract][Full Text] [Related]
17. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
Lim CN; Salem AH
Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
[TBL] [Abstract][Full Text] [Related]
18. Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75.
Bokser L; Bajusz S; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7100-4. PubMed ID: 2205853
[TBL] [Abstract][Full Text] [Related]
19. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group.
Sharifi R; Soloway M
J Urol; 1990 Jan; 143(1):68-71. PubMed ID: 2104638
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in the rat.
English HF; Santner SJ; Levine HB; Santen RJ
Cancer Res; 1986 Jan; 46(1):38-42. PubMed ID: 3079588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
